<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563614</url>
  </required_header>
  <id_info>
    <org_study_id>DepoRaCe</org_study_id>
    <nct_id>NCT01563614</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the Safety &amp; Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) &amp; Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain</brief_title>
  <official_title>Safety and Efficacy of Liposomal Cytarabine in Combination With Radiotherapy (RT) and Lomustine for the Treatment of Leptomeningeal Metastasis From Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mundipharma Research GmbH &amp; Co KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to test the safety and tolerance of the combination therapy with
      cytarabine, lomustine and radiotherapy in patients with leptomeningeal metastasis from
      malignant melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No patients can be recruited for this trial anymore due to other therapeutical approaches that
    became available.
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/Tolerance</measure>
    <time_frame>30 weeks</time_frame>
    <description>The primary endpoint is safety and tolerance and will be based on the frequency and severity of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delay of treatments</measure>
    <time_frame>30 weeks</time_frame>
    <description>Frequency and median time of delay of each of the treatments (lomustine, liposomal cytarabine, radiotherapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>30 weeks</time_frame>
    <description>Overall response rate determined by clinical, MRI- and CSF-cytological assessment criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression</measure>
    <time_frame>30 weeks</time_frame>
    <description>Neurological progression, progression free survival, overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Leptomeningeal Metastasis From Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)</intervention_name>
    <description>Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomustine</intervention_name>
    <description>Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal cytarabine</intervention_name>
    <description>Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Malignant melanoma (including melanoma of unknown primary site, recurrent and
             pretreated systemic melanoma and/or melanoma with parenchymal CNS metastases) with
             leptomeningeal metastasis as demonstrated by a positive CSF (cerebrospinal liquor)
             cytology AND/OR by the presence of characteristic signs and symptoms of leptomeningeal
             metastasis supported by an MRI scan indicating the presence of meningeal tumour

          -  CSF flow abnormalities must be excluded

          -  Males or females â‰¥ 18 years of age

          -  Karnofsky Performance Status &gt; 50%

          -  Adequate organ function (adequate bone marrow reserve, adequate liver function,
             adequate renal function. adequate blood clotting)

        Exclusion Criteria:

          -  Unresected parenchymal brain metastases with a diameter &gt; 3 cm

          -  Prior non melanoma malignancy (unless adequately treated carcinoma in situ of the
             cervix or non melanoma skin cancer)

          -  Prior intrathecal chemotherapy

          -  Prior treatment with systemic cytarabine or nitrosureas

          -  The patient ist pregnant or breast feeding

          -  Severe, active co-morbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Glas, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurologische Universitaetsklinik Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurologische Universitaetsklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>PD Dr. Martin Glas</investigator_full_name>
    <investigator_title>Deputy Director Division of Clinical Neurooncology Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

